Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 20832753 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Yang Q, et al. (2010) Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell 18, 258-67 20832753
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S403-p - PML (human) ▲
Orthologous residues
PML (human): S403‑p, PML iso2 (human): S403‑p, PML iso3 (human): S403‑p, PML iso4 (human): S403‑p, PML iso11 (human): S403‑p, PML iso14 (human): S403‑p, PML (mouse): S409‑p, PML iso2 (mouse): S409‑p, PML (rat): ‑
Characterization
 Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK5 (human)
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered

T409-p - PML (human) ▲
Orthologous residues
PML (human): T409‑p, PML iso2 (human): T409‑p, PML iso3 (human): T409‑p, PML iso4 (human): T409‑p, PML iso11 (human): T409‑p, PML iso14 (human): T409‑p, PML (mouse): T417‑p, PML iso2 (mouse): T417‑p, PML (rat): ‑
Characterization
 Methods used to characterize site in vivo:  mass spectrometry (in vitro), mutation of modification site
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), HeLa (cervical), MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  mouse
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE ERK5 (human)
Downstream Regulation
 Effect of modification (process):  carcinogenesis, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.